CompletedNCT00305370
Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolarity and ADHD
Medication studyAges 8–17Brazil
Understand this study
Who was this study for?
Listed age limits: 8 years to 17 years.
- Listed locations
- Porto AlegreSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Federal University of Rio Grande do Sul
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Brazil
- Age range
- From 8 Years to 17 Years
- Official registry ID
- NCT00305370
- Official title
Show the full official title
Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Porto Alegre
Questions about this study
Who is behind this study?
The study sponsor is Federal University of Rio Grande do Sul, a university.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 8 years to 17 years.
